AN2 Therapeutics, Inc. Increase Decrease In Operating Lease Liability
AN2 Therapeutics, Inc. (ANTX) reported Increase Decrease In Operating Lease Liability of -$53.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2025-03-25
- AN2 Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2023-12-31 was $0.00.
- AN2 Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2023-09-30 was -$13.00K.
- AN2 Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2023-06-30 was -$21.00K.
- AN2 Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2023-03-31 was -$19.00K.
- AN2 Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$53.00K.
- AN2 Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$77.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$13.00K derived: sum of 2 quarters · filed 2025-03-25 | -$34.00K derived: sum of 3 quarters · filed 2025-03-25 | -$53.00K 10-K · filed 2025-03-25 |
| 2023-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$34.00K derived: sum of 2 quarters · filed 2024-11-13 | -$53.00K 10-Q · filed 2024-11-13 | -$73.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$40.00K 10-Q · filed 2024-08-13 | -$60.00K derived: sum of 3 quarters · filed 2024-08-13 | -$80.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$19.00K 10-Q · filed 2024-05-14 | -$39.00K derived: sum of 2 quarters · filed 2024-05-14 | -$59.00K derived: sum of 3 quarters · filed 2024-05-14 | -$78.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$40.00K derived: sum of 2 quarters · filed 2024-03-29 | -$59.00K derived: sum of 3 quarters · filed 2024-03-29 | -$77.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$39.00K derived: sum of 2 quarters · filed 2023-11-09 | -$57.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$37.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$18.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |